LUMOSA THERAPEUTICS CO., LTD. Financials Lumosa Therapeutics Co., Ltd.
Equities
6535
TW0006535008
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 183.5 TWD | -7.56% |
|
-2.65% | +168.67% |
| 05-14 | Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson | CI |
| 05-14 | Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 5,194 | 6,117 | 11,268 | 30,273 | - |
| Enterprise Value (EV) 1 | 5,194 | 6,117 | 11,268 | 30,014 | 29,319 |
| P/E ratio | - | - | -46.5 x | -75.5 x | 38.6 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 240 x | 352 x | - | 531 x | 19.3 x |
| EV / Revenue | 240 x | 352 x | - | 527 x | 18.7 x |
| EV / EBITDA | - | - | - | -82.9 x | 26.6 x |
| EV / FCF | - | -13.5 x | - | -80.9 x | 61.3 x |
| FCF Yield | - | -7.4% | - | -1.24% | 1.63% |
| Price to Book | - | 3.1 x | - | 30.3 x | 17 x |
| Nbr of stocks (in thousands) | 147,345 | 151,973 | 164,974 | 164,974 | - |
| Reference price 2 | 35.25 | 40.25 | 68.30 | 183.5 | 183.5 |
| Announcement Date | 3/25/21 | 3/4/22 | 4/1/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | 21.65 | 17.36 | - | 57 | 1,570 |
| EBITDA 1 | - | - | - | -362 | 1,102 |
| EBIT 1 | - | -430.3 | - | -368 | 1,077 |
| Operating Margin | - | -2,478.27% | - | -645.61% | 68.6% |
| Earnings before Tax (EBT) 1 | - | - | - | -429 | 1,035 |
| Net income 1 | -322.6 | - | -238 | -401 | 786 |
| Net margin | -1,489.83% | - | - | -703.51% | 50.06% |
| EPS 2 | - | - | -1.470 | -2.430 | 4.760 |
| Free Cash Flow 1 | - | -452.7 | - | -371 | 478 |
| FCF margin | - | -2,607.34% | - | -650.88% | 30.45% |
| FCF Conversion (EBITDA) | - | - | - | - | 43.38% |
| FCF Conversion (Net income) | - | - | - | - | 60.81% |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/25/21 | 3/4/22 | 4/1/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.634 | 10.06 | 4.463 | 15 | 18 | 20 | 6 |
| EBITDA 1 | - | - | -78.77 | -92 | -91 | -90 | - |
| EBIT 1 | -103.2 | -149.8 | -80.87 | -101 | -99 | -88 | -85 |
| Operating Margin | -16,279.02% | -1,488.23% | -1,812.03% | -673.33% | -550% | -440% | -1,416.67% |
| Earnings before Tax (EBT) 1 | - | - | -117.6 | -103 | -110 | -109 | - |
| Net income 1 | - | - | -115.6 | -96 | -103 | -102 | - |
| Net margin | - | - | -2,590.61% | -640% | -572.22% | -510% | - |
| EPS 2 | - | - | -0.7100 | -0.5800 | -0.6200 | -0.6200 | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/4/22 | 5/14/24 | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 259 | 954 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -453 | - | -371 | 478 |
| ROE (net income / shareholders' equity) | - | 5.18% | - | -41.8% | 6.9% |
| ROA (Net income/ Total Assets) | - | 4.64% | - | -32.8% | 9.19% |
| Assets 1 | - | - | - | 1,221 | 8,553 |
| Book Value Per Share 2 | - | 13.00 | - | 6.060 | 10.80 |
| Cash Flow per Share 2 | - | - | - | -2.220 | 2.990 |
| Capex 1 | - | 0.09 | - | 2 | 2 |
| Capex / Sales | - | 0.5% | - | 3.51% | 0.13% |
| Announcement Date | 3/25/21 | 3/4/22 | 4/1/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
183.5
TWD
Average target price
2.25
TWD
Spread / Average Target
-98.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +168.67% | 942M | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| -12.64% | 22.22B | |
| +0.44% | 22.27B | |
| -4.18% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +37.41% | 12.52B | |
| -23.95% | 8.34B |
- Stock Market
- Equities
- 6535 Stock
- Financials Lumosa Therapeutics Co., Ltd.